These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32605642)

  • 41. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.
    Le MH; Le DM; Baez TC; Wu Y; Ito T; Lee EY; Lee K; Stave CD; Henry L; Barnett SD; Cheung R; Nguyen MH
    J Hepatol; 2023 Aug; 79(2):287-295. PubMed ID: 37040843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease.
    Kim HY; Baik SJ; Lee HA; Lee BK; Lee HS; Kim TH; Yoo K
    Sci Rep; 2020 Oct; 10(1):17491. PubMed ID: 33060775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome.
    Bae JC; Kim SK; Han JM; Kwon S; Lee DY; Kim J; Park SE; Park CY; Lee WY; Oh KW; Park SW; Rhee EJ
    Diabetes Res Clin Pract; 2017 Jul; 129():136-143. PubMed ID: 28527304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults.
    Zhang J; Xu Q; Lai F; Chen N; Lin M; Liu Y; Zhang W; Liu C; Wang S; Li Z
    BMJ Open Diabetes Res Care; 2021 Aug; 9(1):. PubMed ID: 34433546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.
    Wijarnpreecha K; Li F; Lundin SK; Suresh D; Song MW; Tao C; Chen VL; Lok ASF
    Aliment Pharmacol Ther; 2023 May; 57(9):1014-1027. PubMed ID: 36815445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Longitudinal analysis of risk of non-alcoholic fatty liver disease in adulthood.
    Cuthbertson DJ; Brown E; Koskinen J; Magnussen CG; Hutri-Kähönen N; Sabin M; Tossavainen P; Jokinen E; Laitinen T; Viikari J; Raitakari OT; Juonala M
    Liver Int; 2019 Jun; 39(6):1147-1154. PubMed ID: 30347485
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals.
    Fukuda T; Hamaguchi M; Kojima T; Hashimoto Y; Ohbora A; Kato T; Nakamura N; Fukui M
    Liver Int; 2016 Feb; 36(2):275-83. PubMed ID: 26176710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of weight loss and improved metabolic health status on the risk of non-alcoholic fatty liver disease-results from a prospective cohort in China.
    Huang X; Ouyang W; Hu Y; Tang B; He Y; Wu H; Yang P; Yin L; Liu Q; Chen K; Deng J; Li X; Li Y
    Front Nutr; 2023; 10():1239996. PubMed ID: 38094922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease.
    Konerman MA; Walden P; Joseph M; Jackson EA; Lok AS; Rubenfire M
    Aliment Pharmacol Ther; 2019 Feb; 49(3):296-307. PubMed ID: 30561027
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of metabolically healthy obesity on the risk of incident gastric cancer: a population-based cohort study.
    Hashimoto Y; Hamaguchi M; Obora A; Kojima T; Fukui M
    BMC Endocr Disord; 2020 Jan; 20(1):11. PubMed ID: 31959179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of the Dynamic Change of Metabolic Health Status on the Incident Type 2 Diabetes: A Nationwide Population-Based Cohort Study.
    Kim JA; Kim DH; Kim SM; Park YG; Kim NH; Baik SH; Choi KM; Han K; Yoo HJ
    Endocrinol Metab (Seoul); 2019 Dec; 34(4):406-414. PubMed ID: 31884741
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population.
    Kuang M; Lu S; Xie Q; Peng N; He S; Yu C; Qiu J; Sheng G; Zou Y
    BMC Gastroenterol; 2022 Jun; 22(1):311. PubMed ID: 35752753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects.
    Kim SS; Cho HJ; Kim HJ; Kang DR; Berry JR; Kim JH; Yang MJ; Lim SG; Kim S; Cheong JY; Cho SW
    Dig Liver Dis; 2018 Apr; 50(4):370-377. PubMed ID: 29398414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study.
    VanWagner LB; Khan SS; Ning H; Siddique J; Lewis CE; Carr JJ; Vos MB; Speliotes E; Terrault NA; Rinella ME; Lloyd-Jones DM; Allen NB
    Liver Int; 2018 Apr; 38(4):706-714. PubMed ID: 28963767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipid profile pattern in pediatric overweight population with or without NAFLD in relation to IDF criteria for metabolic syndrome: a preliminary study.
    Bălănescu A; Bălănescu P; Comănici V; Stan I; Acs B; Prisăcariu L; Brezan F; Ciomârtan T; Gherghina I
    Rom J Intern Med; 2018 Mar; 56(1):47-54. PubMed ID: 29080393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents.
    Ayonrinde OT; Oddy WH; Adams LA; Mori TA; Beilin LJ; de Klerk N; Olynyk JK
    J Hepatol; 2017 Sep; 67(3):568-576. PubMed ID: 28619255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects.
    Gummesson A; Strömberg U; Schmidt C; Kullberg J; Angerås O; Lindgren S; Hjelmgren O; Torén K; Rosengren A; Fagerberg B; Brandberg J; Bergström G
    PLoS One; 2018; 13(8):e0202666. PubMed ID: 30133541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Transition in Metabolic Health and Obesity on the Incident Chronic Kidney Disease: A Nationwide Cohort Study.
    Cho YK; Lee J; Kim HS; Park JY; Lee WJ; Kim YJ; Jung CH
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31967306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
    Ampuero J; Aller R; Gallego-Durán R; Banales JM; Crespo J; García-Monzón C; Pareja MJ; Vilar-Gómez E; Caballería J; Escudero-García D; Gomez-Camarero J; Calleja JL; Latorre M; Albillos A; Salmeron J; Aspichueta P; Lo Iacono O; Francés R; Benlloch S; Fernández-Rodríguez C; García-Samaniego J; Estévez P; Andrade RJ; Turnes J; Romero-Gómez M;
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1260-1270. PubMed ID: 30353552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.